Ways to increase the effectiveness of hypertension correction during antitumor therapy with the use of VEGF inhibitors

Abstract

In recent years, cardioncology has rapidly become responsible for comprehensive decision-making appropriate cancer patients receiving cardiotoxic cancer therapy. Currently, the implementation of a multidisciplinary approach in the correction of adverse events using various drug antitumor therapy regimens is becoming increasingly relevant. In particular, given the widespread use of vascular-endothelial growth factor inhibitors, both at the heart of complex schemes and in mono-supportive modes. It is important to timely identify and correct such a clinically significant adverse event as an increase in blood pressure at the time of administration and in the early follow-up period. Adherence to standard drug regimens for hypertension, which usually provide satisfactory blood pressure control between cycles of administration of vascular-endothelial growth factor inhibitors, in a number of patients did not allow the same effective retention of blood pressure in the planned intervals with the administration of bevacizumab. The intensification of drug therapy for hypertension, both at the pre-infusion stage and at the time of an increase in blood pressure, was of a multidirectional nature.

Search and summarize information on the availability and development of physiotherapeutic treatment methods for the correction of hypertension during antitumor therapy in cancer patients using vascular-endothelial growth factor inhibitors. 35 literature sources were analyzed. There are no data on the development of physiotherapeutic methods for the treatment of bevacizumab-induced hypertension. Domestic sources ― 25 articles. Foreign sources ― 10 articles.

An analysis of the literature concluded that there is a lack of research on the development of physiotherapeutic methods for the treatment of bevacizumab-induced hypertension. In order to reduce the cardiotoxicity of humanized recombined monoclonal antibodies, maintain the dose interval period, improve survival and eliminate the need for dose adjustment of antihypertensive drugs, it is proposed to consider the use of preformed physical factors in the treatment of bevacizumab-induced hypertension.

Keywords

vascular-endothelial growth factor / hypertension / physiotherapy / quality of life / cancer patient

References

[1] Khan MA, Razumov AH, Korchazhkina NB, Pogonchenkova IV. Physical and rehabilitation medicine in paediatrics. Moscow: GEOTAR-Media; 2018. 408 р. (In Russ)..

[2] Хан М.А., Разумов A.H., Корчажкина Н.Б., Погонченкова И.В. Физическая и реабилитационная медицина в педиатрии. Москва: ГЭОТАР-Медиа, 2018. 408 с.

[3] Mal GS, Artyushkova EB, Bykanova AM, et al. The problem of bevacizumab-induced arterial hypertension as a phenomenon of cardiotoxicity in colorectal cancer patients. Modern Problems Science Education. 2022;(4):114. EDN: CUPQTA doi: 10.17513/spno.31949

[4] Маль Г.С., Артюшкова Е.Б., Быканова А.М. и др. Проблема бевацизумаб-индуцированной артериальной гипертензии как явление кардиотоксичности у пациентов с колоректальным раком // Современные проблемы науки и образования. 2022. № 4. С. 114. EDN: CUPQTA doi: 10.17513/spno.31949

[5] Wu S, Kim C, Baer L, et al. Bevacizumab increases risk for severe proteinuria in cancer patients. J Am Society Nephrol. 2010;21(8):1381–1389. doi: 10.1681/ASN.2010020167

[6] Wu S., Kim C., Baer L., et al. Bevacizumab increases risk for severe proteinuria in cancer patients // J Am Society Nephrol. 2010. Vol. 21, N 8. P. 1381–1389. doi: 10.1681/ASN.2010020167

[7] Li M, Kroetz DL. Bevacizumab-induced hypertension: Clinical presentation and molecular understanding. Pharmacol Ther. 2018;(182):152–160. doi: 10.1016/j.pharmthera.2017.08.012

[8] Li M., Kroetz D.L. Bevacizumab-induced hypertension: Clinical presentation and molecular understanding // Pharmacol Ther. 2018. N 182. P. 152–160. doi: 10.1016/j.pharmthera.2017.08.012

[9] Carter JJ, Fretwell LV, Woolard J. Effects of 4 multitargeted receptor tyrosine kinase inhibitors on regional hemodynamics in conscious, freely moving rats. FASEB J. 2017;31(3):1193–1203. DOI: 10.1096/fj.201600749R

[10] Carter J.J., Fretwell L.V., Woolard J. Effects of 4 multitargeted receptor tyrosine kinase inhibitors on regional hemodynamics in conscious, freely moving rats // FASEB J. 2017. Vol. 31, N 3. P. 1193-1203. DOI: 10.1096/fj.201600749R

[11] Gladchenko MP, Artyushkova EB, Mal GS, et al. Influence of bevacizumab on hemodynamic indicators of older regulatory Wistar rats. Modern Problems Science Education. 2021;(6):143. EDN: VYIEJL doi: 10.17513/spno.31280

[12] Гладченко М.П., Артюшкова Е.Б., Маль Г.С., и др. Влияние бевацизумаба на гемодинамические показатели стареющих нормотензивных крыс линии Wistar // Современные проблемы науки и образования. 2021. № 6. С. 143. EDN: VYIEJLdoi: 10.17513/spno.31280

[13] Xu R, Xu C, Liu C, et al. Efficacy and safety of bevacizumab-based combination therapy for treatment of patients with metastatic colorectal cancer. OncoTargets Therapy. 2018;(11):8605–8621. doi: 10.2147/OTT.S171724

[14] Xu R., Xu C., Liu C., et al. Efficacy and safety of bevacizumab-based combination therapy for treatment of patients with metastatic colorectal cancer // OncoTargets Therapy. 2018. N 11. P. 8605–8621. doi: 10.2147/OTT.S171724

[15] Cao D, Zheng Y, Xu H, et al. Bevacizumab improves survival in metastatic colorectal cancer patients with primary tumor resection: A meta-analysis. Sci Rep. 2019;9(1):20326. doi: 10.1038/s41598-019-56528-2

[16] Cao D., Zheng Y., Xu H., et al. Bevacizumab improves survival in metastatic colorectal cancer patients with primary tumor resection: A meta-analysis // Sci Rep. 2019. Vol. 9, N 1. P. 20326. doi: 10.1038/s41598-019-56528-2

[17] Zhao T, Wang X, Xu T, et al. Bevacizumab significantly increases the risks of hypertension and proteinuria in cancer patients: A systematic review and comprehensive meta-analysis. Oncotarget. 2017;8(31):51492–51506.doi: 10.18632/oncotarget.18190

[18] Zhao T., Wang X., Xu T., et al. Bevacizumab significantly increases the risks of hypertension and proteinuria in cancer patients: A systematic review and comprehensive meta-analysis // Oncotarget. 2017. Vol. 8, N 31. P. 51492–51506.doi: 10.18632/oncotarget.18190

[19] Cai J, Ma H, Huang F, et al. Correlation of bevacizumab-induced hypertension and outcomes of metastatic colorectal cancer patients treated with bevacizumab: A systematic review and meta-analysis. World J Surg Oncol. 2013;(11):306. doi: 10.1186/1477-7819-11-306

[20] Cai J., Ma H., Huang F., et al. Correlation of bevacizumab-induced hypertension and outcomes of metastatic colorectal cancer patients treated with bevacizumab: A systematic review and meta-analysis // World J Surg Oncol. 2013. N 11. Р. 306.doi: 10.1186/1477-7819-11-306

[21] Pinto C, Antonuzzo L, Porcu L, et al. Efficacy and safety of bevacizumab combined with fluoropyrimidine monotherapy for unfit or older patients with metastatic colorectal cancer: A systematic review and meta-analysis. Clin Colorectal Cancer. 2017;16(2):e61–e72. doi: 10.1016/j.clcc.2016.08.006

[22] Pinto C., Antonuzzo L., Porcu L., et al. Efficacy and safety of bevacizumab combined with fluoropyrimidine monotherapy for unfit or older patients with metastatic colorectal cancer: A systematic review and meta-analysis // Clin Colorectal Cancer. 2017. Vol. 16, N 2. Р. e61–e72.doi: 10.1016/j.clcc.2016.08.006

[23] Wu YS, Shui L, Shen D, Chen X. Bevacizumab combined with chemotherapy for ovarian cancer: An updated systematic review and meta-analysis of randomized controlled trials. Oncotarget. 2017;8(6):10703–10713 doi: 10.18632/oncotarget.12926

[24] Wu Y.S., Shui L., Shen D., Chen X. Bevacizumab combined with chemotherapy for ovarian cancer: An updated systematic review and meta-analysis of randomized controlled trials // Oncotarget. 2017. Vol. 8, N 6. Р. 10703–10713.doi: 10.18632/oncotarget.12926

[25] Belenkov YuN, Oganov RG. Cardiology. National manual. Moscow: GEOTAR-Media; 2008. 1232 р. (In Russ).

[26] Беленков Ю.Н., Оганов Р.Г. Кардиология. Национальное руководство. Москва: ГЭОТАР-Медиа, 2008. 1232 с.

[27] Alekseeva LA, Vakhlakov AN, Sergeeva EV, et al. Fatal and nonfatal cardiovascular complications in patients with essential hypertension (hypertensive disease) during follow-up for many years. Cardiology. 2002;(4):23–28. EDN: MOTBMV

[28] Alekseeva L.A., Vakhlakov A.N., Sergeeva E.V., et al. Fatal and nonfatal cardiovascular complications in patients with essential hypertension (hypertensive disease) during follow-up for many years // Cardiology. 2002. N 4. P. 23–28. EDN: MOTBMV

[29] Gogin EE. Hypertensive disease is the main cause of cardiovascular morbidity and mortality in Russia. Ther Arch. 2003;75(9):31–36. EDN: OJZQWX

[30] Гогин Е.Е. Гипертоническая болезнь: основная причина, определяющая сердечно-сосудистую заболеваемость и смертность в стране // Терапевтический архив. 2003. Т. 75, № 9. С. 31–36. EDN: OJZQWX

[31] Kearney P, Whelton M, Reynolds K, et al. Worldwide prevalence of hypertension: A systematic review. Hypertens. 2004;(22):11–19. doi: 10.1097/00004872-200401000-00003

[32] Kearney P., Whelton M., Reynolds K., et al. Worldwide prevalence of hypertension: А systematic review // Hypertens. 2004. N 22. P. 11–19. doi: 10.1097/00004872-200401000-00003

[33] Asai I, Heller R, Kajii E. Hypertension control and medication increase in primary care. J Hum Hypertens. 2002;16(5):313–318. doi: 10.1038/sj.jhh.1001385

[34] Asai I., Heller R., Kajii E. Hypertension control and medication increase in primary care // J Hum Hypertension. 2002. Vol. 16. N 5. P. 313–318. doi: 10.1038/sj.jhh.1001385

[35] Shlyakhto EV, Conradi AO. Hypertension. Pathogenesis and progression from the perspective of neurogenic mechanisms. Cardiovasc Ther Prevent. 2003;2(3):22–26. EDN: YSYDSP

[36] Шляхто Е.В., Конради А.О. Гипертоническая болезнь. Патогенез и прогрессирование с позиции нейрогенных механизмов // Кардиоваскулярная терапия и профилактика. 2003. Т. 2, № 3. С. 22–26. EDN: YSYDSP

[37] Wilson K, Gibson N, Willan A, Cook D. Effect of smoking cessation on mortality after myocardial infarction: meta-analysis of cohort studies. Arch Intern Med. 2000;160(7):939–944. doi: 10.1001/archinte.160.7.939

[38] Wilson K., Gibson N., Willan A., Cook D. Effect of smoking cessation on mortality after myocardial infarction: Meta-analysis of cohort studies // Arch Intern Med. 2000. Vol. 160, N 7. P. 939–944. doi: 10.1001/archinte.160.7.939

[39] Almazov VA, Tsyrlin VA, Shlyakhto EV. Neurogenic and cellular mechanisms of arterial hypertension. In: I Congress of the Association of Cardiologists of CIS countries: A collection of Abstract

[40] Алмазов В.А., Цырлин В.А., Шляхто Е.В. Нейрогенные и клеточные механизмы артериальных гипертоний // I Конгресс ассоциации кардиологов стран СНГ: сборник тезисов, 20–23 мая 1997 года. Москва, 1997. С. 135.

[41] s, 20–23 May 1997. Moscow; 1997. Р. 135. (In Russ).

[42] Князева Т.А., Бадтиева В.А. Физиобальнеотерапия сердечно-сосудистых заболеваний. Москва: МЕДпресс-информ, 2008. 264 c.

[43] Knyazeva TA, Badtieva VA. Physiobalneotherapy for cardiovascular diseases. Moscow; 2008. 264 p.

[44] Готовский М.Ю. Магнитотерапия и ее место в современной медицине // Традиционная медицина. 2010. № 3. С. 4–10. EDN: MVDHRJ

[45] Gotovsky MY. Magnetic therapy and its place in modern medicine. Traditsionnaya Meditsina. 2010;(3):4–10. EDN: MVDHRJ

[46] Улащик В.С. Теоретические и практические аспекты общей магнитотерапии // Вопросы курортологии, физиотерапии и лечебной физической культуры. 2001. № 5. С. 3–8.

[47] Ulashchik VS. Theoretical and practical aspects of general magnetotherapy. Issues of balneology, physiotherapy and therapeutic physical culture. 2001;(5):3–8.

[48] Абрамович С.Г., Федотченко А.А., Корякина А.В., и др. Особенности геропротекторного действия магнитотерапии у пожилых больных с сочетанной сердечно-сосудистой патологией // Вопросы курортологии, физиотерапии и лечебной физической культуры. 1999. № 5. С. 7–9. EDN: SFVMLH

[49] Abramovich SG, Fedotchenko AA, Koryakina AV, et al. Features of the geroprotective effect of magnetic therapy in elderly patients with concomitant cardiovascular pathology. Questions of balneology, physiotherapy and physical therapy. 1999;(5):7–9. EDN:SFVMLH

[50] Абрамович С.Г., Корякина А.В., Бородач Л.Н., и др. Опыт применения общей магнитотерапии в лечении больных с сердечно-сосудистыми заболеваниями пожилого возраста // Сборник тезисов и докладов Первого Российского съезда геронтологов и гериатров. Самара, 1999. 16 с.

[51] Abramovich SG, Koryakina AV, Borodach LN, et al. Experience of using general magnetic therapy in the treatment of elderly patients with cardiovascular diseases. Collection of abstracts and reports of the First Russian Congress of Gerontologists and Geriatricians. Samara; 1999. 16 p.

[52] Абрамович С.Г., Куликов А.Г., Долбилкин А.Ю. Общая магнитотерапия при артериальной гипертонии // Физиотерапия, бальнеология и реабилитация. 2014. Т. 13, № 5. С. 50–55. EDN: SXLYHV

[53] Abramovich SG, Kulikov AG, Dolbilkin AYu. General magnetic therapy for arterial hypertension. Physiotherapy, balneology and rehabilitation. 2014;13(5):50–55. EDN: SXLYHV

[54] Шумский В.И., Гилинская Н.Ю., Петрицкая Е.Н., и др. Общая магнитотерапия в лечении гипертонической болезни. Учебное пособие // Физиотерапия, бальнеология и реабилитация. 2007. № 2. С. 51–53.

[55] Shumsky VI, Gilinskaya NYu, Petritskaya EN, et al. General magnetic therapy in the treatment of hypertension. Tutorial. Physiotherapy, balneology and rehabilitation. 2007;(2):51–53.

[56] Хан М.А., Петрова М.С., Дегтярева М.Г., и др. Современные технологии физической реабилитации детей с перинатальным поражением центральной нервной системы // Вестник восстановительной медицины. 2021. Т. 20, № 4. С. 57–64. EDN: PWFNUF doi: 10.38025/2078-1962-2021-20-4-57-64

[57] Khan MA, Petrova MS, Degtyareva MG, et al. Modern technologies of physical rehabilitation of children with perinatal damage to the central nervous system. Bulletin of Restorative Medicine. 2021;20(4):57–64. EDN: PWFNUF doi: 10.38025/2078-1962-2021-20-4-57-64

[58] Мамиконян Н.Р. Инновационная магнитотерапия в лечении гипертонической болезни: Автореф. дис. ... канд. мед. наук: 14.03.11. Место защиты: Центральная государственная медицинская академия Управления делами Президента Российской Федерации. Москва, 2018. 26 с..

[59] Mamikonyan NR. Innovative magnetotherapy in the treatment of hypertension [dissertation abstract]: 14.03.11. Place of defence: Central State Medical Academy of the Administration of Affairs of the President of the Russian Federation. Moscow; 2018. 26 р. (In Russ).

[60] Хабарова О.И. Реабилитация больных сочетанной патологией стабильной стенокардией и гипертонической болезнью применением укороченных курсов азотных ванн и электромагнитных полей сверхвысокой частоты: Автореф. дис. ... канд. мед. наук: 14.03.11. Место защиты: Том. науч.-исслед. ин-т курортологии и физиотерапии МЗ РФ. Томск, 2010. 24 с..

[61] Khabarova OI. Rehabilitation of patients with a combined pathology of stable angina pectoris and hypertension by application of shortened courses of nitrogen baths and electromagnetic fields of ultra-high frequency [dissertation abstract]: 14.03.11. Place of defence: Tomsk Research Institute of Balneology and Physiotherapy. Tomsk; 2010. 24 p. (In Russ).

[62] Галлямов А.Г., Загидуллин Ш.З., Валеев Р.Г., Галлямова Н.А. ДМВ-терапия и хлоридно-натриевые ванны в сочетании с медикаментозной терапией у больных артериальной гипертензией // Физиотерапия, бальнеология и реабилитация. 2007. № 2. С. 11–13.

[63] Gallyamov AG, Zagidullin ShZ, Valeev RG, Gallyamova NA. DMV therapy and sodium chloride baths in combination with drug therapy in patients with arterial hypertension. Physiotherapy, balneology and rehabilitation. 2007;(2):11–13.

[64] Гаркави Л.Х., Квакина Е.Б., Кузьменко Т.С. Антистрессорные реакции и активационная терапия. Реакция активации как путь к здоровью через процессы самоорганизации. Москва: ИМЕДИС, 1998. 565 с.

[65] Garkavi LKh, Kvakina EB, Kuzmenko TS. Anti-stress reactions and activation therapy. The activation reaction as a path to health through self-organization processes. Moscow: IMEDIS; 1998. 565 р. (In Russ).

[66] Галлямов А.Г., Валеев Р.Г., Галлямова Н.А. Влияние комплексного лечения физическими факторами на мозговое кровообращение больных с начальными проявлениями дисциркуляторной энцефалопатии // Вопросы курортологии, физиотерапии и лечебной физической культуры. 2001. № 4. С. 44–45.

[67] Gallyamov AG, Valeev RG, Gallyamova NA. The influence of complex 35 treatment with physical factors on the cerebral circulation of patients with initial manifestations of dyscirculatory encephalopathy. Problems Balneology Physiotherapy Exercise Therapy. 2001;(4):44–45.

[68] Владимирский Е.В., Фильцагина Т.Н. Проблемы антигипертензивной бальнеотерапии // Вопросы курортологии, физиотерапии и лечебной физической культуры. 2013. Т. 90, № 5. С. 40–45. EDN: RTEILZ5.

[69] Vladimirsky EV, Filtsagina TN. The problems of antihypertensive balneotherapy. Problems Balneology Physiotherapy Exercise Therapy. 2013;90(5):40–45. EDN: RTEILZ5.

[70] Антонюк М.В., Гвозденко Т.А. Рекреационные ресурсы Дальнего Востока и возможности применения в профилактике и восстановительном лечении // Здоровье, медицинская экология, наука. 2013. № 1. С. 12–18. EDN: RCHYDL.

[71] Antonyuk MV, Gvozdenko TA. Recreational resources of the Far East and possibilities of application in prevention and rehabilitation treatment. Health, medical ecology, science. 2013; (1):12–18. EDN: RCHYDL

[72] Никифорова Т.И. Физические факторы в лечении мягкой артериальной гипертонии: Автореф. дис. ... канд. мед. наук: 14.00.51, 14.00.06. Место защиты: Рос. науч. центр восстанов. мед. и курортологии. Москва, 2002. 36 с.

[73] Nikiforova TI. Physical factors in the treatment of mild arterial hypertension [dissertation abstract]: 14.00.51, 14.00.06. Place of protection: Russian Scientific Centre for Restorative Medicine and Balneology. Moscow; 2002. 36 p. (In Russ)..

[74] Хан М.А. Восстановительная медицина в системе оздоровления детей и подростков. Москва, 2007. С. 453–472.

[75] Khan MA. Regenerative medicine in the system of health improvement for children and adolescents. Moscow; 2007. Р. 453–472.

[76] Каладзе Н.Н., Зюкова И.Б., Скоромная Н.Н., Швец А.В. Опыт применения электросон-терапии у детей с сердечно-сосудистой и ревматологической патологией // Вестник физиотерапии и курортологии. 2015. Т. 21, № 2. С. 58–62. EDN: YRGRLJ

[77] Kaladze NN, Zyukova IB, Skoromnaya NN, Shvets AV. Experience of using electrosleep therapy in children with cardiovascular and rheumatological pathologies. Bulletin of physiotherapy and balneology. 2015;21(2):58–62. EDN:YRGRLJ

[78] Райгородский Ю.М., Болотова Н.В. Лукьянов В.Ф., Компаниец О.В. Магнитная симпатокоррекция при мягкой артериальной гипертонии // Физиотерапия, бальнеология и реабилитация. 2014. № 2. С. 30–35. EDN: SCPUVD

[79] Raigorodsky YuM, Bolotova NV, Lukyanov VF, Kompaniets OV. Magnetic sympathocorrection for mild arterial hypertension. Physiotherapy, balneology and rehabilitation. 2014;(2):30–35. EDN: SCPUVD

[80] Боголюбов В.М. Физиотерапия и курортология. Книга II. Москва: Бином, 2022. 312 с.

[81] Bogolyubov VM. Physiotherapy and spa treatment. Book II. Moscow: Binom; 2022. 312 р. (In Russ).

RIGHTS & PERMISSIONS

Eco-Vector